Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

• On 2026‑04‑07 Fennec announced an investigator‑sponsored Phase I/II open‑label trial at the University of Arizona Cancer Center.
• The study evaluates PEDMARK® (sodium thiosulfate) as an otoprotectant in adult and adolescent/young‑adult patients receiving cisplatin chemotherapy for head & neck or testicular cancers.
• Primary endpoints: hazard‑ratio risk reduction in ototoxicity versus historical controls and systemic elimination of unbound cisplatin up to 6 hours post‑infusion.
• The trial adds to three other recently launched institution‑led studies (Tampa General Hospital, City of Hope, STS‑J01 Japan) aimed at expanding real‑world evidence for broader label use.

• The release is classified by the company as Non‑Material – Positive because it represents operational/clinical progress without an immediate financial effect.
• Compared with prior news (e.g., Feb 20 head & neck real‑world data rated “Material – Positive”), this announcement provides incremental evidence rather than a breakthrough that would materially shift revenue expectations or valuation in the short term.
• No financing, partnership, regulatory approval, or sales impact is disclosed; therefore the market reaction is expected to be modest.

Fennec Pharmaceuticals develops PEDMARK®, an FDA‑approved sodium thiosulfate injection that prevents cisplatin‑induced ototoxicity in pediatric solid‑tumor patients (approval Sep 2022). The drug also carries an NCCN 2A recommendation for adolescent/young‑adult use. Beyond the pediatric indication, Fennec is generating real‑world data across adult head‑&‑neck and testicular germ‑cell populations to support potential label expansion into larger oncology markets.